Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.31298 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.
Eur J Cancer
January 2025
University of Perugia, Unit of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy.
A unique collaboration of multi-disciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to two-centimeter safety margins. For a correct stage classification and treatment decision, a sentinel lymph node biopsy shall be offered in patients with tumor thickness ≥ 1.
View Article and Find Full Text PDFEndocrine effects of MEK and BRAF inhibitor therapy in paediatric patients: a tertiary centre experience.
J Neurooncol
December 2024
UCL Great Ormond Street Institute of Child Health, University College London, London, UK.
Purpose: BRAF and MEK inhibitors are used to treat a range of paediatric tumours including low-grade gliomas. The ubiquitous nature of the BRAF/MAPK/MEK pathway means such treatments are not without side effects such as renal tubulopathies and hyperglycaemia. This study aims to describe the endocrine dysfunction observed in a cohort of children treated with BRAF and MEK inhibitors at the largest paediatric centre in the UK utilising these treatments.
View Article and Find Full Text PDFNeoadjuvant systemic therapy for inoperable differentiated thyroid cancers: Impact on tumor resectability.
Surgery
January 2025
Division of Medical Oncology, Banner M.D. Anderson Cancer Center, Gilbert, AZ.
Background: Limited treatment options exist for inoperable thyroid cancers. We evaluated whether neoadjuvant use of systemic tyrosine kinase inhibitors facilitates surgery of differentiated thyroid cancers in this challenging context.
Methods: A single-institution experience of 42 patients receiving tyrosine kinase inhibitors for papillary, follicular and anaplastic thyroid carcinomas between 2018 and 2023 was reviewed to identify differentiated thyroid cancers treated with neoadjuvant tyrosine kinase inhibitors (dabrafenib/trametinib, lenvatinib/pembrolizumab, or lenvatinib alone) via multidisciplinary protocols.
BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country.
Front Oncol
September 2024
Department of Pediatrics, King Hussein Cancer Center, Amman, Jordan.
Introduction: Most pediatric low-grade-gliomas (LGG) and some high-grade-gliomas (HGG) have alterations in the RAS/MAPK pathway. Promising high tumor response rates were achieved using BRAF/MEK inhibitors, however data on their use in low-middle-income-countries (LMICs) are limited.
Methods: We retrospectively reviewed our Jordanian experience of using compassionate BRAF/MEK inhibitors in treating children with gliomas.
Rosai-Dorfman-Destombes disease in adults: a single center experience.
Ann Hematol
November 2024
Division of Hematology, University of British Columbia, Vancouver, BC, Canada.
Recent advances in Rosai-Dorfman-Destombes disease (RDD), notably molecular testing, targeted therapy, and PET-CT imaging, hold promise for better recognition and improved outcomes. This study presents patients diagnosed and treated in a "real world" setting, where navigating limited resources must be considered. This retrospective single-center review includes 15 adult patients diagnosed with RDD at Vancouver General Hospital between November 2015 and October 2023.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!